Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05169333
Other study ID # The ORFAN Study
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 23, 2016
Est. completion date February 2030

Study information

Verified date May 2023
Source University of Oxford
Contact Kingham
Email orfan@cardiov.ox.ac.uk
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.


Description:

The ORFAN registry will include unselected, consecutive patients undergoing CT scans (coronary CT angiograms (CCTA), CT chest, abdomen and pelvis scans) collected at the participating centres. The study will combine imaging data with patient demographics and clinical information (including prospective outcomes) to aid the development and/or validation of new or existing image analysis algorithms and software tools to improve diagnosis, clinical risk discrimination and prediction. Specifically, ORFAN will evaluate the specificity, utility and predictive value of newly developed image analysis methods. ORFAN will recruit and follow-up patients prospectively, linking the index CT scan with blood biomarkers, genetic information as well as information on disease progression (recorded through follow-up CT scans) and clinical outcomes data. The study will also collect CT scans performed in the past and link them with clinical factors and prospective outcomes data collected after the index scan was performed.


Recruitment information / eligibility

Status Recruiting
Enrollment 250000
Est. completion date February 2030
Est. primary completion date February 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: Inclusion Criteria for study Arms 1, 2 and 3: - Participant is willing and able to give informed consent for participation in the study. - Male or Female, aged 18 -99 years. Inclusion Criteria for study Arm 4: • Male or Female, aged 18 -99 years. Exclusion Criteria: Exclusion Criteria for Study Arms 1, 2 and 3: - Unable or unwilling to consent - Active cancer Exclusion Criteria for Study Arm 4: - Participation in Study Arms 1, 2 or 3 - Existing opt-out from use of data for research purposes

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Australia Flinders University Adelaide
Australia The University of Sydney Sydney
Belgium University Hospitals Leuven Leuven
China Fudan University Shanghai
China TEDA International Cardiovascular Hospital Tianjin
France Almaviva Sante - Clinique Axium Aix-en-Provence
Germany Friedrich-Alexander-Universitat Erlangen-Nurmberg Erlangen
Germany University Hospital Ulm Ulm
Greece Lefkos Stavros Clinic Athens
Hungary MTA-SE Cardiovascular Imaging Research Group Budapest
Italy Centro Cardiologico Monzino IRCCS, University of Milan Milan
Japan Oita University Oita
Korea, Republic of Seoul National University Seoul
Netherlands Amsterdam Universitair Medische Centra Amsterdam
Netherlands Zuyderland Medical Centre Sittard
Romania University of Medicine and Pharmacy of Targu Mures Târgu-Mures
United Arab Emirates Cleveland Clinic Abu Dhabi Abu Dhabi
United Kingdom Royal United Hospitals Bath NHS Foundation Trust Bath
United Kingdom Sandwell and West Birmingham Hospitals NHS Trust Birmingham
United Kingdom University Hospitals Birmingham NHS Trust Birmingham
United Kingdom Royal Papworth Hospital NHS Trust Cambridge
United Kingdom University of Edinburgh, Royal Infirmary Edinburgh
United Kingdom Golden Jubilee National Hospital Glasgow
United Kingdom NHS Greater Glasgow and Clyde Glasgow
United Kingdom Leeds Teaching Hospitals NHS Trust Leeds
United Kingdom University Hosptials of Leicester NHS Trust Leicester
United Kingdom Barts Health NHS Trust London
United Kingdom Guy's and St Thomas' NHS Foundation Trust London
United Kingdom Royal Brompton and Harefield Hospitals London
United Kingdom University Hospital of Manchester NHS Foundation Trust Manchester
United Kingdom Milton Keynes University Hospital Milton Keynes
United Kingdom Oxford University Hospitals NHS Foundation Trust Oxford
United Kingdom Heart and Lung Centre, New Cross Hospital Wolverhampton
United States NIH National Heart, Lunch, and Blood Institute Bethesda Maryland
United States Cleveland Clinic Heart and Vascular Institute Cleveland Ohio
United States Mayo Clinic Rochester Minnesota

Sponsors (7)

Lead Sponsor Collaborator
University of Oxford British Heart Foundation, Caristo Diagnostics Limited, European Commission, Innovate UK, National Consortium of Intelligent Medical Imaging, Oxford University Hospitals NHS Trust

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  China,  France,  Germany,  Greece,  Hungary,  Italy,  Japan,  Korea, Republic of,  Netherlands,  Romania,  United Arab Emirates,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiac and all cause mortality Using novel image analysis methods, clinical risk factors, and blood biomarkers to predict future cardiac and all-cause mortality over a period of 15 years post CT scan. 15 years
Primary Non-fatal vascular events Using novel image analysis methods, clinical risk factors, and blood biomarkers to predict future non-fatal vascular events over a period of 15 years post CT scan. 15 years
Primary Cardiac and non-cardiac findings by Computed Tomography Using novel image analysis methods, clinical risk factors, and blood biomarkers to detect pathology from Computed Tomography images. 15 years
Primary Progression of disease Using novel image analysis methods, clinical risk factors, and blood biomarkers to predict progression of cardiometabolic diseases over a period of 15 years post index CT scan. 15 years
Secondary Cardiovascular risk factors Using novel image analysis methods and blood biomarkers, to detect and monitor cardiovascular risk factors and responsiveness to routine clinical care 15 years
Secondary Hospital admissions for any reason classified using ICD10 Using novel image analysis methods, to predict hospital admissions over a period of 15 years post CT scan 15 years
Secondary Genotyping Using genotyping to predict clinical phenotypes 15 years
Secondary Progression of cardiovascular disease Using novel image analysis methods, clinical risk factors, and blood biomarkers to predict disease progression measured by CT scans 15 years
Secondary Validation and refinement of the CaRi Image analysis platform Validate the prognostic and diagnostic performance of CaRi Image analysis platform against the other study outcomes 15 years
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)